Annovis Bio

Founded in May 2008 by Maria Maccecchini, Annovis Bio is a clinical stage biotechnology company based in Malvern, Pennsylvania, developing treatments for neurodegenerative conditions like Alzheimer's and Parkinson's. Operating as a publicly traded entity on the New York Stock Exchange since its initial public offering in January 2020, the firm employs a core team of fifteen individuals. The enterprise focuses on inhibiting the production of multiple neurotoxic proteins to restore brain function, advancing its lead oral drug candidate called buntanetap. Recent clinical data from 2024 showed buntanetap improved motor function in Phase 3 trials for early Parkinson's disease and demonstrated efficacy in Phase 2 and 3 trials for Alzheimer's. Guided by Principal Financial Officer Andrew Walsh and Audit Committee Chairman Reid McCarthy, the pipeline also includes ANVS405 for traumatic brain injury and ANVS301 for later stage dementia.